Antibacterial Susceptibility Testing in the Clinical Laboratory

Infectious Disease Clinics of North America

Volumn 23, Issue 4, 2009, Pages 757-790

  Holland, Thomas L ^a   Woods, Christopher W ^a,b   Joyce, Maria ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Antibiotic; Bacteria; Gram negative; Gram positive; Resistance; Susceptibility

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; MIKAMYCIN B; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TIMENTIN; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER INFECTION; AGAR DILUTION; ALPHA HEMOLYTIC STREPTOCOCCUS; ANAEROBE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUTOANALYSIS; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BIOLOGICAL WARFARE; BROTH DILUTION; BURKHOLDERIA CEPACIA; CLINICAL LABORATORY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORYNEBACTERIUM INFECTION; DISK DIFFUSION; ENDOCARDITIS; ENTEROBACTERIACEAE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; GENOTYPE; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; INTERMETHOD COMPARISON; LISTERIOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; REVIEW; SCREENING; SERUM BACTERICIDAL ACTIVITY; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 70350714137     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.06.001     Document Type: Review

References (221)

1. Bates D.W., Goldman L., and Lee T.H. Contaminant blood cultures and resource utilization: the true consequences of false-positive results. JAMA 265 (1991) 365-369
2. Ferraro M.J. Should we reevaluate antibiotic breakpoints?. Clin Infect Dis 33 Suppl 3 (2001) S227-S229
3. Gould I.M., MacKenzie F.M., Struelens M.J., et al. Towards a European strategy for controlling antibiotic resistance Nijmegen, Holland August 29-31, 1999. Clin Microbiol Infect 6 (2000) 670-674
4. Jorgensen J.H., and Ferraro M.J. Antimicrobial susceptibility testing: general principles and contemporary practices. Clin Infect Dis 26 (1998) 973-980
5. Reller L.B., Schoenknecht F.D., Kenny M.A., et al. Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media. J Infect Dis 130 (1974) 454-463
6. D'Amato R.F., Thornsberry C., Baker C.N., et al. Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin. Antimicrob Agents Chemother 7 (1975) 596-600
7. CLSI. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement (2008), CLSI, Wayne (PA)
8. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). EUCAST Definitive Document E.DEF 2.1, August 2000: determination of antimicrobial susceptibility test breakpoints. Clin Microbiol Infect 6 (2000) 570-572
9. rd edition (2004), CLSI, Wayne (PA)
10. Jorgensen J.H., and Turnidge J.D. Susceptibility test methods: dilution and disk diffusion methods. In: Murray P.R., Baron E.J., Jorgensen J.H., et al. (Eds). Manual of clinical microbiology. 9th edition (2007), American Society for Microbiology, Washington (DC) 1152-1172
11. Labbe A.C., Bourgault A.M., Vincelette J., et al. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob Agents Chemother 43 (1999) 2517-2519
12. Bauer A.W., Kirby W.M., Sherris J.C., et al. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 45 (1966) 493-496
13. Jorgensen J.H., and Ferraro M.J. Antimicrobial susceptibility testing: special needs for fastidious organisms and difficult-to-detect resistance mechanisms. Clin Infect Dis 30 (2000) 799-808
14. Evangelista A.T., and Truant A.L. Rapid systems and instruments for antimicrobial susceptibility testing of bacteria. In: Truant A.L. (Ed). Manual of commercial methods in medical microbiology (2002), American Society of Microbiology, Washington (DC) 413-429
15. Richter S.S., and Ferraro M.J. Susceptibility testing instrumentation and computerized expert systems for data analysis and interpretation. In: Murray P.R., Baron E.J., and Jorgensen J.H. (Eds). Manual of clinical microbiology. 9th edition (2007), American Society for Microbiology, Washington (DC) 245-256
16. Food and Drug Administration. Review criteria for assessment of antimicrobial susceptibility (1991), Food and Drug Administration, Rockville (MD)
17. Korgenski E.K., and Daly J.A. Evaluation of the BIOMIC video reader system for determining interpretive categories of isolates on the basis of disk diffusion susceptibility results. J Clin Microbiol 36 (1998) 302-304
18. Medeiros A.A., and Crellin J. Evaluation of the Sirscan automated zone reader in a clinical microbiology laboratory. J Clin Microbiol 38 (2000) 1688-1693
19. Nijs A., Cartuyvels R., Mewis A., et al. Comparison and evaluation of Osiris and Sirscan 2000 antimicrobial susceptibility systems in the clinical microbiology laboratory. J Clin Microbiol 41 (2003) 3627-3630
20. Barenfanger J., Drake C., and Kacich G. Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing. J Clin Microbiol 37 (1999) 1415-1418
21. Doern G.V., Vautour R., Gaudet M., et al. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 32 (1994) 1757-1762
22. Kerremans J.J., Verboom P., Stijnen T., et al. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother 61 2 (2008) 428-435
23. Bruins M., Oord H., Bloembergen P., et al. Lack of effect of shorter turnaround time of microbiological procedures on clinical outcomes: a randomised controlled trial among hospitalised patients in the Netherlands. Eur J Clin Microbiol Infect Dis 24 5 (2005) 305-313
24. Jett B., Free L., and Sahm D.F. Factors influencing the Vitek gram-positive susceptibility system's detection of vanB-encoded vancomycin resistance among enterococci. J Clin Microbiol 34 (1996) 701-706
25. Katsanis G.P., Spargo J., Ferraro M.J., et al. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol 32 (1994) 691-696
26. Tenover F.C., Swenson J.M., O'Hara C.M., et al. Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. J Clin Microbiol 33 (1995) 1524-1527
27. Doern G.V., Scott D.R., Rashad A.L., et al. Evaluation of a direct blood culture disk diffusion antimicrobial susceptibility test. Antimicrob Agents Chemother 20 (1981) 696-698
28. Mirrett S., and Reller L.B. Comparison of direct and standard antimicrobial disk susceptibility testing for bacteria isolated from blood. J Clin Microbiol 10 (1979) 482-487
29. Ling T.K., Liu Z.K., and Cheng A.F. Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gram-negative bacilli from positive blood cultures. J Clin Microbiol 41 (2003) 4705-4707
30. Malhotra-Kumar S., Haccuria K., Michiels M., et al. Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococcus species. J Clin Microbiol 46 5 (2008) 1577-1587
31. Baker C.N., Stocker S.A., Culver D.H., et al. Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 29 (1991) 533-538
32. Huang M.B., Baker C.N., Banerjee S., et al. Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol 30 (1992) 3243-3248
33. Schulz J.E., and Sahm D.F. Reliability of the E test for detection of ampicillin, vancomycin, and high-level aminoglycoside resistance in Enterococcus spp. J Clin Microbiol 31 (1993) 3336-3339
34. Walsh T.R., Bolmstrom A., Qwarnstrom A., et al. Evaluation of a new E test for detecting metallo-beta-lactamases in routine clinical testing. J Clin Microbiol 40 (2002) 2755-2759
35. Fuchs P.C., Barry A.L., and Brown S.D. Evaluation of daptomycin susceptibility testing by E test and the effect of different batches of media. J Antimicrob Chemother 48 (2001) 557-561
36. Hill G.B. Spiral gradient endpoint: a new method of susceptibility testing. Hosp Pract (Off Ed) 25 Suppl 4 (1990) 31-37
37. Wootton M., Howe R.A., Hillman R., et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47 4 (2001) 399-403
38. Craig W.A. Qualitative susceptibility tests versus quantitative MIC tests. Diagn Microbiol Infect Dis 16 (1993) 231-236
39. Jorgensen J.H. Selection of antimicrobial agents for routine testing in a clinical microbiology laboratory. Diagn Microbiol Infect Dis 16 (1993) 245-249
40. Greenwood D. Detection of antibiotic resistance in vitro. Int J Antimicrob Agents 14 (2000) 303-306
41. Peterson L.R., and Shanholtzer C.J. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev 5 (1992) 420-432
42. Shanholtzer C.J., Peterson L.R., Mohn M.L., et al. MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques. Antimicrob Agents Chemother 26 (1984) 214-219
43. Wolfson J.S., and Swartz M.N. Drug therapy: serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med 312 (1985) 968-975
44. Hallander H.O., Dornbusch K., Gezelius L., et al. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother 22 (1982) 743-752
45. Aaron S.D., Ferris W., Henry D.A., et al. multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 161 (2000) 1206-1212
46. Aaron S.D., Vandemheen K.L., Ferris W., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366 9484 (2005) 463-471
47. Rasheed J.K., and Tenover F.C. Detection and characterization of antimicrobial resistance genes in bacteria. In: Murray P.R., Baron E.J., and Pfaller M.A. (Eds). Manual of clinical microbiology (2003), American Society of Microbiology, Washington (DC) 1196-1212
48. Tenover F.C. Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond. Clin Infect Dis 44 3 (2007) 418-423
49. Deguchi T., Yasuda M., Asano M., et al. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 39 (1995) 561-563
50. Rasheed J.K., Jay C., Metchock B., et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 41 (1997) 647-653
51. Rasheed J.K., Anderson G.J., Yigit H., et al. Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother 44 (2000) 2382-2388
52. Arbique J., Forward K., Haldane D., et al. Comparison of the Velogene rapid MRSA identification assay, Denka MRSA-screen assay, and BBL crystal MRSA ID system for rapid identification of methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 40 (2001) 5-10
53. Marshall A., and Hodgson J. DNA chips: an array of possibilities. Nat Biotechnol 16 (1998) 27-31
54. Hope R., Livermore D.M., Brick G., et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62 Suppl 2 (2008) ii65-ii74
55. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin resistant Staphylococcus aureus infections in the United States. JAMA 298 (2007) 1763-1771
56. Livermore D.M. Antibiotic resistance in staphylococci. Int J Antimicrob Agents 16 Suppl 1 (2000) S3-S10
57. King M.D., Humphrey B.J., Wang Y.F., et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144 5 (2006) 309-317
58. Corey G.R., and Boucher H.W. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 Suppl 5 (2008) S344-S349
59. Katayama Y., Ito T., and Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 44 (2000) 1549-1555
60. Crisostomo M.I., Westh H., Tomasz A., et al. The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci U S A 98 (2001) 9865-9870
61. Schmitz F.J., Fluit A.C., Gondolf M., et al. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. J Antimicrob Chemother 43 (1999) 253-259
62. Ito T., Katayama Y., Asada K., et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45 (2001) 1323-1336
63. Ma X.X., Ito T., Tiensasitorn C., et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 46 (2002) 1147-1152
64. Finan J.E., Rosato A.E., Dickinson T.M., et al. Conversion of oxacillin resistant staphylococci from heterotypic to homotypic resistance expression. Antimicrob Agents Chemother 46 (2002) 24-30
65. Huang M.B., Gay T.E., Baker C.N., et al. Two percent sodium chloride is required for susceptibility testing of staphylococci with oxacillin when using agar-based dilution methods. J Clin Microbiol 31 (1993) 2683-2688
66. Yamazumi T., Marshall S.A., Wilke W.W., et al. Comparison of the Vitek gram-positive susceptibility 106 card and the MRSAscreen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus. J Clin Microbiol 39 (2001) 53-56
67. Swenson J.M., and Tenover F.C. Results of disk diffusion testing with cefoxitin correlate with presence of mecA in Staphylococcus spp. J Clin Microbiol 43 8 (2005) 3818-3823
68. Velasco D., del Mar Tomas M., Cartelle M., et al. Evaluation of different methods for detecting methicillin (oxacillin) resistance in Staphylococcus aureus. J Antimicrob Chemother 55 (2005) 379-382
69. Proctor R.A., Kahl B., Von Eiff C., et al. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis 27 Suppl 1 (1998) S68-S74
70. Baron E.J. Implications of new technology for infectious diseases practice. Clin Infect Dis 43 (2006) 1318-1323
71. Rossney A.S., Herra C.M., Brennan G.I., et al. Evaluation of the xpert methicillin-resistant Staphylococcus aureus (MRSA) assay using the genexpert real-time PCR platform for rapid detection of MRSA from screening specimens. J Clin Microbiol 46 10 (2008) 3285-3290
72. Hiramatsu K., Hanaki H., Ino T., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
73. Tenover F.C., and Moellering R.C. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44 9 (2007) 1208-1215
74. Maor Y., Rahav G., Belausov N., et al. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 45 5 (2007) 1511-1514
75. Sader HS, Jones RN, Rybak MJ. Evaluation of the accuracy of the Etest Macromethod for the detection of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) strains. Poster session presented at 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28, 2008; Washington DC.
76. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46 2 (2008) 193-200
77. Lina G., Quaglia A., Reverdy M.E., et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 43 (1999) 1062-1066
78. Roberts M.C., Sutcliffe J., Courvalin P., et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43 (1999) 2823-2830
79. Zelazny A.M., Ferraro M.J., Glennen A., et al. Selection of strains for quality assessment of the disk induction method for detection of inducible clindamycin resistance in staphylococci: a CLSI collaborative study. J Clin Microbiol 43 6 (2005) 2613-2615
80. Frank A.L., Marcinak J.F., Mangat P.D., et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 21 (2002) 530-534
81. Panagea S., Perry J.D., and Gould F.K. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci?. J Antimicrob Chemother 44 (1999) 581-582
82. Rao G.G. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci?. J Antimicrob Chemother 45 (2000) 715
83. Siberry G.K., Tekle T., Carroll K., et al. Failure of clindamycin treatment of methicillin resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37 (2003) 1257-1260
84. Johnson A.P., and Livermore D.M. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal. Lancet 354 (1999) 2012-2013
85. Pillai S.K., Sakoulas G., Wennersten C., et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 186 (2002) 1603-1607
86. Tsiodras S., Gold H.S., Sakoulas G., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
87. Brauers J., Kresken M., Hafner D., et al. Surveillance of linezolid resistance in Germany, 2001-2002. Clin Microbiol Infect 11 (2005) 39-46
88. Jevitt L.A., Thorne M., Traczewski M.M., et al. Multicenter evaluation of the E test and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus Isolates. J Clin Microbiol 44 9 (2006) 3098-3104
89. Pankey G.A. Tigecycline. J Antimicrob Chemother 56 3 (2005) 470-480
90. Bishara J., Pitlik S., Samra Z., et al. Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis 9 (2003) 1168-1169
91. Markowitz N., Quinn E.L., and Saravolatz L.D. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 117 (1992) 390-398
92. Schmitz F.J., Verhoef J., Fluit A., et al. Stability of the MICs of various antibiotics in different clonal populations of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 41 (1998) 311-313
93. Yeldandi V., Strodtman R., and Lentino J.R. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 22 (1988) 873-880
94. Sievert D.M., Rudrik J.T., Patel J.B., et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46 5 (2008) 668-674
95. Bogdanovich T., Ednie L.M., et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (2005) 4210-4219
96. Graham J.C., and Gould F.K. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 49 (2002) 437-444
97. Mulazimoglu L., Drenning S.D., and Muder R.R. Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 40 (1996) 1534-1535
98. Mulligan M.E., Murray-Leisure K.A., Ribner B.S., et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 94 (1993) 313-328
99. Watanakunakorn C., and Tisone J.C. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 22 (1982) 903-905
100. O'Neill A.J., Cove J.H., and Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 47 (2001) 647-650
101. Wichelhaus T.A., Boddinghaus B., Besier S., et al. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002) 3381-3385
102. Perazzi B., Fermepin M.R., Malimovka A., et al. Accuracy of cefoxitin disk testing for characterization of oxacillin resistance mediated by penicillin-binding protein 2a in coagulase-negative staphylococci. J Clin Microbiol 44 10 (2006) 3634-3639
103. Schwalbe R.S., Stapleton J.T., and Gilligan P.H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316 (1987) 927-931
104. Jones R.N., Ross J.E., Castanheira M., et al. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 62 4 (2008) 416-426
105. Vergis E.N., Hayden M.K., Chow J.W., et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 135 (2001) 484-492
106. Fontana R., Canepari P., Lleo M.M., et al. Mechanisms of resistance of enterococci to beta-lactam antibiotics. Eur J Clin Microbiol Infect Dis 9 (1990) 103-105
107. Murdoch D.R., Mirrett S., Harrell L.J., et al. Sequential emergence of antibiotic resistance in enterococcal bloodstream isolates over 25 years. Antimicrob Agents Chemother 46 (2002) 3676-3678
108. Okhuysen P.C., Singh K.V., and Murray B.E. Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam. Diagn Microbiol Infect Dis 17 (1993) 219-224
109. Weinstein M.P. Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol 39 (2001) 2729-2731
110. Weinstein M.P., Mirrett S., Kannangara S., et al. Multicenter evaluation of use of penicillin and ampicillin as surrogates for in vitro testing of susceptibility of enterococci to imipenem. J Clin Microbiol 42 8 (2004) 3747-3751
111. El Amin N., Wretlind B., Wenger A., et al. Ampicillin-sensitive, imipenem resistant strains of Enterococcus faecium. J Clin Microbiol 40 (2002) 738
112. Leclercq R., Derlot E., Duval J., et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 319 (1988) 157-161
113. Boyd D.A., Cabral T., Van Caeseele P., et al. Molecular characterization of the vanE gene cluster in vancomycin-resistant Enterococcus faecalis N00-410 isolated in Canada. Antimicrob Agents Chemother 46 (2002) 1977-1979
114. Depardieu F., Reynolds P.E., and Courvalin P. VanD-type vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 47 (2003) 7-18
115. Dutta I., and Reynolds P.E. Biochemical and genetic characterization of the vanC-2 vancomycin resistance gene cluster of Enterococcus casseliflavus ATCC 25788. Antimicrob Agents Chemother 46 (2002) 3125-3132
116. Malani P.N., Thal L., Donabedian S.M., et al. Molecular analysis of vancomycin-resistant Enterococcus faecalis from Michigan hospitals during a 10 year period. J Antimicrob Chemother 49 (2002) 841-843
117. Nelson R.R. Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. J Hosp Infect 42 (1999) 275-282
118. Kiehlbauch J.A., Hannett G.E., Salfinger M., et al. Use of the national committee for clinical laboratory standards guidelines for disk diffusion susceptibility testing in New York State laboratories. J Clin Microbiol 38 (2000) 3341-3348
119. Rosenberg J., Tenover F.C., Wong J., et al. Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci?. J Clin Microbiol 35 (1997) 2526-2530
120. Kohner P.C., Patel R., Uhl J.R., et al. Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin. J Clin Microbiol 35 (1997) 3258-3263
121. Murdoch D.R., Mirrett S., Harrell L.J., et al. Comparison of microscan broth microdilution, synergy quad plate agar dilution, and disk diffusion screening methods for detection of high-level aminoglycoside resistance in enterococcus species. J Clin Microbiol 41 (2003) 2703-2705
122. Jorgensen J.H., Crawford S.A., Kelly C.C., et al. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 47 (2003) 3760-3763
123. Richter S.S., Kealey D.E., Murray C.T., et al. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 52 (2003) 123-127
124. Centers for Disease Control. Preventing pneumococcal disease among infants and young children. MMWR Recomm Rep 49 RR09 (2000) 1-38
125. Centers for Disease Control and Prevention. Assessment of susceptibility testing practices for Streptococcus pneumoniae-United States, February 2000. MMWR Morb Mortal Wkly Rep 51 (2002) 392-394
126. Breiman R.F., Butler J.C., Tenover F.C., et al. Emergence of drug resistant pneumococcal infections in the United States. JAMA 271 (1994) 1831-1835
127. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45 (2001) 1721-1729
128. Doern G.V., Richter S.S., Miller A., et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin Infect Dis 41 2 (2005) 139-148
129. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease following the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 (2003) 1737-1746
130. Moore M.R., Gertz R.E., Woodbury R.L., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 197 7 (2008) 1016-1027
131. Hanage W.P., Huang S.S., Lipsitch M., et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 195 3 (2007) 347-352
132. Appelbaum P.C. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 34 (2002) 1613-1620
133. Ward J.I., and Moellering Jr. R.C. Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin. Antimicrob Agents Chemother 20 (1981) 204-207
134. Witte W. Antibiotic resistance in gram-positive bacteria: epidemiological aspects. J Antimicrob Chemother 44 Suppl A (1999) 1-9
135. Klugman K.P. The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50 Suppl S2 (2002) 1-5
136. Perez-Trallero E., Marimon J.M., Gonzalez A., et al. Spain14-5 international multiresistant Streptococcus pneumoniae clone resistant to fluoroquinolones and other families of antibiotics. J Antimicrob Chemother 51 (2003) 715-719
137. Zhanel G.G., Palatnick L., Nichol K.A., et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob Agents Chemother 47 (2003) 1867-1874
138. Tenover F.C., Baker C.N., and Swenson J.M. Evaluation of commercial methods for determining antimicrobial susceptibility of Streptococcus pneumoniae. J Clin Microbiol 34 (1996) 10-14
139. Fukushima K.Y., Yanagihara K., Hirakata Y., et al. Rapid identification of penicillin and macrolide resistance genes and simultaneous quantification of Streptococcus pneumoniae in purulent sputum samples by use of a novel real-time multiplex PCR assay. J Clin Microbiol 46 7 (2008) 2384-2388
140. Jorgensen J.H., Barry A.L., Traczewski M.M., et al. Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2. J Clin Microbiol 38 (2000) 2814-2818
141. Rosser S.J., Alfa M.J., Hoban S., et al. E test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci. J Clin Microbiol 37 (1999) 26-30
142. Douglas C.P., Siarakas S., and Gottlieb T. Evaluation of E test as a rapid method for determining MICs for nutritionally variant streptococci. J Clin Microbiol 32 (1994) 2318-2320
143. Raney P.M., Tenover F.C., Carey R.B., et al. Investigation of inducible clindamyinc and telithromycin resistance in isolates of β-hemolytic streptococci. Diagn Microbiol Infect Dis 55 3 (2006) 213-218
144. CLSI. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved standard M45-A (2006), CLSI, Wayne (PA)
145. Safdar A., and Armstrong D. Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). J Clin Microbiol 41 (2003) 483-485
146. Moellering Jr. R.C., Medoff G., Leech I., et al. Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother 1 (1972) 30-34
147. Jorgensen J.H., and Hindler J.E. New consensus guidelines from the clinical and laboratory standards institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis 44 2 (2007) 280-286
148. Soriano F., Zapardiel J., and Nieto E. Antimicrobial susceptibilities of corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents. Antimicrob Agents Chemother 39 (1995) 208-214
149. Logan N.A., Popovic T., and Hoffmaster A. Bacillus and other aerobic endospore-forming bacteria. In: Murray P.R., Baron E.J., and Jorgensen J.H. (Eds). Manual of clinical microbiology. 9th edition (2007), American Society for Microbiology, Washington (DC) 455-473
150. Medeiros A.A. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 24 Suppl 1 (1997) S19-S45
151. Paterson D.L., and Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18 4 (2005) 657-686
152. Schwaber M.J., and Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60 5 (2007) 913-920
153. Moland E.S., Sanders C.C., and Thomson K.S. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among Escherichia coli and Klebsiella isolates with hidden resistance to expanded spectrum cephalosporins and aztreonam?. J Clin Microbiol 36 (1998) 2575-2579
154. Queena A.M., Foleno B., Gownley C., et al. Effects of inoculum and ß-lactamase activity in AmpC- and Extended-Spectrum ß-Lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 42 1 (2004) 269-275
155. Wiegand I., Geiss H.K., Mack D., et al. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol 45 4 (2007) 1167-1174
156. Gavin P.J., Suseno M.T., et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 50 (2006) 2244-2247
157. Thomson K.S., and Smith M.E. Version 2000: the new beta-lactamases of gram-negative bacteria at the dawn of the new millennium. Microbes Infect 2 (2000) 1225-1235
158. Schwaber M.J., Raney P.M., Rasheed J.K., et al. Utility of NCCLS guidelines for identifying extended-spectrum b-lactamases in non- Escherichia coli and non- Klebsiella spp. of Enterobacteriaceae. J Clin Microbiol 42 (2004) 294-298
159. Thomson K.S., Sanders C.C., and Moland E.S. Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens. Antimicrob Agents Chemother 43 (1999) 1393-1400
160. Steward C.D., Mohammed J.M., Swenson J.M., et al. Antimicrobial susceptibility testing of carbapenems: multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates. J Clin Microbiol 41 (2003) 351-358
161. Bush K, Queenan AM. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440-458.
162. Tibbetts R., Frye J.G., Marschall J., et al. Detection of KPC-2 in a clinical isolate of Proteus mirabilis and first reported description of carbapenemase resistance caused by a KPC beta-lactamase in P. mirabilis. J Clin Microbiol 46 9 (2008) 3080-3083
163. Marchaim D., Navon-Venezia S., Schwaber M.J., et al. Isolation of imipenem-resistant Enterobacter species: emergence of kpc-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 52 4 (2008) 1413-1418
164. Tenover F.C., Kalsi R.K., Williams P.P., et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 12 8 (2006) 1209-1213
165. Lee K., Chong Y., Shin H.B., et al. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 7 2 (2001) 88-91
166. Anderson K.F., Lonsway D.R., Rasheed J.K., et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 45 8 (2007) 2723-2725
167. Kelsidis T., Karageorgopoulos D.E., Kelesidis J., et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62 5 (2008) 895-904
168. Crump J.A., Barrett T.J., Nelson J.T., et al. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype typhi and for non-typhi salmonellae. Clin Infect Dis 37 (2003) 75-81
169. Gupta S.K., Medella F., Omondi M.W., et al. Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance. Clin Infect Dis 46 11 (2008) 1656-1663
170. Kadhiravan T., Wig N., Kapil A., et al. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis 5 1 (2005) 37
171. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 34 (2002) 634-640
172. Gales A.C., Reis A.O., and Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39 (2001) 183-190
173. Tam V.H., Gamez E.Z., Weston J.S., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 46 6 (2008) 862-867
174. Morlin G.L., Hedges D.L., Smith A.L., et al. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa. J Clin Microbiol 32 (1994) 1027-1030
175. Thomassen M.J., Demko C.A., Boxerbaum B., et al. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 140 (1979) 873-880
176. Fowerakeri J.E., Laughton C.R., Brown D.F.J., et al. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 55 6 (2005) 921-927
177. Govan J.R., and Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60 (1996) 539-574
178. Burns J.L., Saiman L., Whittier S., et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 39 (2001) 257-260
179. Marley E.F., Mohla C., and Campos J.M. Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 33 (1995) 3191-3193
180. Burns J.L., Saiman L., Whittier S., et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 38 (2000) 1818-1822
181. Neu H.C., Niu W.W., and Chin N.X. Tazobactam prevention of emergence of resistance. Diagn Microbiol Infect Dis 12 (1989) 477-480
182. Saiman L., Mehar F., Niu W.W., et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23 (1996) 532-537
183. Rolston K.V., and Safdar A. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 45 12 (2007) 1602-1609
184. Denton M., and Kerr K.G. Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosis patients. J Clin Microbiol 40 (2002) 1884
185. Tsiodras S., Pittet D., Carmeli Y., et al. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 32 (2000) 651-656
186. Jones R.N., and Sader H.S. Antimicrobial susceptibility of uncommonly isolated non-enteric gram-negative bacilli. Int J Antimicrob Agents 25 2 (2005) 95-109
187. Zhang L., Li X.Z., and Poole K. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45 (2001) 3497-3503
188. Carroll K.C., Cohen S., Nelson R., et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 32 (1998) 229-235
189. Nicodemo A.C., Araujo M.R.E., Ruiz A.S., et al. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, E test and agar dilution methods. J Antimicrob Chemother 53 4 (2004) 604-608
190. Krueger T.S., Clark E.A., and Nix D.E. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 41 (2001) 71-78
191. Zhou J., Chen Y., Tabibi S., et al. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 51 3 (2007) 1085-1088
192. Gaynes R., and Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41 (2005) 848-854
193. Peleg A.Y., Seifert H., and Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21 3 (2008) 538-582
194. Landman D., Quale J.M., Mayorga D., et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, N.Y.: the preantibiotic era has returned. Arch Intern Med 162 (2002) 1515-1520
195. M7-A7 CLSI. Dilution antimicrobial susceptibility tests for bacteria that grow aerobically (2007), CLSI, Wayne (PA)
196. Swenson J.M., Killgore G.E., and Tenover F.C. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J Clin Microbiol 42 (2004) 5102-5108
197. Hoban D.J., Doern G.V., Fluit A.C., et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 32 Suppl 2 (2001) S81-S93
198. Sahm D.F., Jones M.E., Hickey M.L., et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 45 (2000) 457-466
199. Sahm D.F., Brown N.P., Thornsberry C., et al. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 120 3 Suppl 1 (2008) 16-24
200. Critchley I.A., Brown S.D., Traczewski M.M., et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. faropenem surveillance study. Antimicrob Agents Chemother 51 12 (2007) 4382-4389
201. Wang S.A., Harvey A.B., Conner S.M., et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 147 2 (2007) 81-88
202. Jorgensen J.H., Crawford S.A., Fulcher L.C., et al. Multilaboratory evaluation of disk diffusion antimicrobial susceptibility testing of Neisseria meningitidis isolates. J Clin Microbio 44 5 (2006) 1744-1754
203. Biedenbach D.J., and Jones R.N. Comparative assessment of E test for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: investigation using 510(k) review criteria, recommended by the food and drug administration. J Clin Microbiol 34 (1996) 3214-3217
204. Daher O., Lopardo H.A., and Rubeglio E.A. Value of E test penicillin V and penicillin G strips for penicillin susceptibility testing of Neisseria meningitidis. Diagn Microbiol Infect Dis 43 (2002) 119-121
205. Gomez-Herruz P., Gonzalez-Palacios R., Romanyk J., et al. Evaluation of the E test for penicillin susceptibility testing of Neisseria meningitidis. Diagn Microbiol Infect Dis 21 (1995) 115-117
206. Vazquez J.A., Arreaza L., Block C., et al. Interlaboratory comparison of agar dilution and E test methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 47 (2003) 3430-3434
207. Emergence of fluoroquinolone-resistant Neisseria meningitidis-Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep 57 7 (2008) 173-175
208. Hachem C.Y., Clarridge J.E., Reddy R., et al. Antimicrobial susceptibility testing of Helicobacter pylori: comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis 24 (1996) 37-41
209. Osato M.S., Reddy R., Reddy S.G., et al. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 17 (2001) 39-44
210. Liu C.Y., Huang Y.T., Liao C.H., et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 52 9 (2008) 3161-3168
211. Nguyen M.H., Yu V.L., Morris A.J., et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 30 (2000) 870-876
212. CLSI. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 7th edition (2007), CLSI, Wayne (PA)
213. Roe D.E., Finegold S.M., Citron D.M., et al. Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media. Clin Infect Dis 35 Suppl 1 (2002) S40-S46
214. Citron D.M., Ostovari M.I., Karlsson A., et al. Evaluation of the E test for susceptibility testing of anaerobic bacteria. J Clin Microbiol 29 (1991) 2197-2203
215. Hecht D.W. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 12 3 (2006) 115-121
216. Baines S.D., O'Connor R., Freeman J., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62 5 (2008) 1046-1052
217. Al-Nassir W.N., Sethi A.K., Nerandzic M.M., et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 47 1 (2008) 56-62
218. Shapiro D.S., and Schwartz D.R. Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure. J Clin Microbiol 40 (2002) 2278-2281
219. Centers for Disease Control and Prevention. Suspected cutaneous anthrax in a laboratory worker-Texas, 2002. JAMA 287 (2002) 2356-2358
220. Mohammed M.J., Marston C.K., Popovic T., et al. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards both microdilution reference and E test agar gradient diffusion methods. J Clin Microbiol 40 (2002) 1902-1907
221. Perry R.D., and Fetherston J.D. Yersinia pestis: etiologic agent of plague. Clin Microbiol Rev 10 (1997) 35-66